Study record · Delta sleep-inducing peptide
DSIP and 24-hour sleep-wake behaviour in severe chronic insomnia
The study reported improved night sleep, daytime rest and performance, with effects persisting into the first placebo post-treatment night.
Key result
The study reported improved night sleep, daytime rest and performance, with effects persisting into the first placebo post-treatment night.
Study details
Study designPlacebo-controlled, double-blind clinical trial
PopulationMiddle-aged people with severe chronic insomnia
Sample size14
RouteInjection; exact route/dose not stated in indexed abstract
Regimen / exposureDSIP under placebo-controlled double-blind conditions for seven successive nights
Duration7 nights
ComparatorPlacebo baseline / placebo conditions
Primary endpoint / questionNight sleep, daytime rest, alertness and performance
Safety resultModern systematic safety reporting was not provided.
Key limitationsTiny, old single-investigator study; later double-blind work found only weak effects and little likely therapeutic benefit.
Registry / identifierPMID 3622582